Anaphylaxis to antivenom in the background of alpha-gal syndrome ‒ a case report
DOI:
https://doi.org/10.15584/ejcem.2026.3.10Keywords:
alpha-gal syndrome, anaphylaxis, antivenom hypersensitivityAbstract
Introduction and aim. Alpha-gal syndrome is an IgE-mediated allergy to galactose-α-1,3-galactose, typically associated with delayed hypersensitivity reactions following ingestion of mammalian meat. Severe immediate hypersensitivity reactions to equine-derived antivenom in patients with previously unrecognized alpha-gal syndrome are rarely reported. We report one of the first cases from South Asia of refractory anaphylaxis following equine-derived antivenom in a patient with previously undiagnosed alpha-gal syndrome, highlighting an important but under-recognized clinical challenge.
Description of the case. A 45-year-old Sri Lankan woman developed refractory anaphylaxis shortly after administration of equine-derived antivenom for a Russell’s viper bite. She required intravenous adrenaline and noradrenaline infusions, fluid resuscitation, and high-dependency care, with subsequent full recovery. Further evaluation revealed a history suggestive of alpha-gal syndrome, including recurrent urticaria and wheezing following consumption of mammalian meat and dairy products, as well as possible anaphylaxis to wasp stings. Serum alpha-gal–specific IgE levels were markedly elevated.
Conclusion. This case highlights the potential for severe hypersensitivity reactions to mammalian-derived antivenoms in patients with alpha-gal syndrome.
Downloads
References
Commins SP, Platts-Mills TAE. Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal). Curr Allergy Asthma Rep. 2013;13(1):72-77. doi:10.1007/s11882-012-0315-y
Platts-Mills TAE, Commins SP, Biedermann T, et al. On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on understanding IgE-Mediated mammalian meat allergy. J Allergy Clin Immunol. 2020;145:1061-1071. doi:10.1016/j.jaci.2020.01.047
Mabelane T, Basera W, Botha M, Thomas HF, Ramjith J, Levin ME. Predictive values of alpha‐gal IgE levels and alpha‐gal IgE: Total IgE ratio and oral food challenge‐proven meat allergy in a population with a high prevalence of reported red meat allergy. Pediatr Allergy and Immunol. 2018;29(8):841-849. doi:10.1111/pai.12969
Iglesia EGA, Kwan M, Virkud Y V, Iweala OI. Management of food allergies and food-related anaphylaxis. JAMA. 2024;331(6):510-521. doi:10.1001/jama.2023.26857
Dasch GA, Eremeeva ME, Zambrano ML, Premaratna R, Kularatne SAM, Rajapakse RPVJ. Molecular characterisation of Rickettsial agents in ticks (Acari: Ixodidae) from Sri Lanka. Am J Trop Med Hyg. 2022;106(6):1613-1623. doi:10.4269/ajtmh.21-0995
Dasanayake D, Karunatilake C, Karunaratne C, Fernando N, Iddagoda J, de Silva R. Alpha-gal allergy in a South Asian country. BMC Immunol. 2025;26(1):37. doi:10.1186/s12865-025-00717-4
Román-Carrasco P, Hemmer W, Cabezas-Cruz A, Hodžić A, de la Fuente J, Swoboda I. The α-Gal syndrome and potential mechanisms. Front Allergy. 2021;2:783279. doi:10.3389/falgy.2021.783279
Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med. 2008;358:1109-1117. doi:10.1056/NEJMoa074943
Gowda DC, Davidson EA. Structural features of carbohydrate moieties in snake venom glycoproteins. Biochem Biophys Res Commun. 1992;182(1):294-301. doi:10.1016/S0006-291X(05)80144-5
Wai M, Filip AB, Abbott A, Martin A, Donnell R, Sutton J. Anaphylaxis in Alpha-Gal patients treated with F(ab’)2 for snake bite venom. Toxicol Commun. 2024;8(1):2392459 doi:10.1080/24734306.2024.2392459
Filip AB, Mahmood L, Tilly C, et al. Prevalence of adverse drug reactions: Comparing Crotalidae immune polyvalent antivenoms F(ab’)2 and F(ab) in a galactose-alpha-1,3-galactose (alpha-gal) endemic area. Ann Emerg Med. 2026;87(3):292-302. doi:10.1016/j.annemergmed.2025.06.618
Blessmann J, Hanlodsomphou S, Santisouk B, et al. Serum IgE against galactose-alpha-1,3-galactose is common in Laotian patients with snakebite envenoming, but not the major trigger for early anaphylactic reactions to antivenom. Toxicon X. 2020;7:100054. doi:10.1016/j.toxcx.2020.100054
Fischer J, Eberlein B, Hilger C, et al. Alpha-gal is a possible target of IgE-mediated reactivity to antivenom. Allergy. 2017;72(5):764-771. doi: 10.1111/all.13073
Taylor ML. Intrinsic risk factors for alpha-gal syndrome in a case-control study, 2019 to 2020. Ann Allergy Asthma Immunol. 2024:132(6):759-764.e2. doi:10.1016/j.anai.2024.01.029
Kačar M, Rijavec M, Šelb J, Korošec P. Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis. Clin Exp Allergy. 2023:53(4):392-404. doi:10.1111/cea.14264
Banner W, Edelen K, Epperson LC, Moore E. Hypersensitivity reactions due to North American pit viper antivenom administration and confirmed elevation of alpha-gal IgE. Toxicol Commun. 2024;8(1):2314314. doi:10.1080/24734306.2024.2314314
De Silva HA, Ryan NM, De Silva HJ. Adverse reactions to snake antivenom, and their prevention and treatment. Br J Clin Pharmacol. 2016;81(3):446-452. doi:10.1111/bcp.12739
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
